RxDoctor Payments Data

Mary Meadows, PA

Physician Assistant · Charlotte, NCNPI 1679806566

Payments from drug & device makers

$3,386in general payments, 2019–2025

Across 161 payments — averaging $21.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$622
  • Astellas Pharma US Inc$563
  • Urovant Sciences Inc$291
  • Procept Biorobotics Corporation$240
  • Endo Pharmaceuticals Inc.$219
  • Sumitomo Pharma America, Inc.$193
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$3,34399%
  • Education$431%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,386 in reported general payments places this provider in the 85th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$14,266
Medicare patients
121
Services billed
579

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron70$48,674
MyrbetriqMirabegron56$33,765
Tamsulosin Hcl372$6,563
Potassium Citrate ErPotassium Citrate69$6,296
Silodosin22$2,143
Dutasteride41$1,987
Finasteride153$1,456
Solifenacin Succinate24$626
Oxybutynin Chloride ErOxybutynin Chloride17$586
Alfuzosin Hcl ErAlfuzosin Hcl23$332
Oxybutynin Chloride13$147
NitrofurantoinNitrofurantoin Macrocrystal12$122

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$193$48,67470 claims
Astellas Pharma US IncMyrbetriq$563$33,76556 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →